Search

Researchers from Duke University Medical Center conducted a study on the metabolic effects of the SGLT2 inhibitor dapagliflozin in heart failure patients with varying ejection fractions. The study found that dapagliflozin altered ketone and fatty acid metabolism in heart failure with reduced ejection fraction but not in heart failure with preserved ejection fraction. The research suggests that changes in key pathways related to fatty acid and amino acid metabolism could serve as therapeutic targets across different heart failure subtypes. The study was funded by various organizations including AstraZeneca and the National Institutes of Health. [Extracted from the article]